Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen.
We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3-6 vaccine doses.
Chakvetadze
Catherine
C
Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, 75 970 Paris, France.
Bani-Sadr
Firouzé
F
Le Pendeven
Catherine
C
Lescure
François-Xavier
FX
Fontaine
Camille
C
Galperine
Tatiana
T
Slama
Laurence
L
Bonnard
Philippe
P
Mariot
Philippe
P
Soussan
Patrick
P
Pialoux
Gilles
G
D000328:Adult; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000009:adverse effects* / Q000276:immunology*; D006801:Humans; D007156:Immunologic Memory; D008297:Male; D008875:Middle Aged
D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D017325:Hepatitis B Vaccines